SHIP1 Inhibitors to Augment Blood Cell Production and Transplantation and Kill Cancer Cells

SUNY Upstate Medical University researchers have developed a class of small molecule compounds that show promise for treating multiple myeloma and myelosuppression that occurs with many cancer treatments. These drugs inhibit a gene called SHIP1 — a novel target in cancer treatment — and have been shown to kill cancer cells in the lab and extend life in animal models of multiple myeloma. In addition, SHIP1 inhibitors have been shown to increase blood cell production, and so may have applications as an adjunct to cancer therapies that destroy platelets. The drug would provide a desirable alternative to present protein-drug therapies.  More...

Patent Information:
Technology/Start-up ID: